-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – It-hMSC in Dementia Associated With Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - It-hMSC in Dementia Associated With Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. It-hMSC in Dementia Associated With Alzheimer's Disease Drug Details:...
-
Product Insights
Dermatological Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatological Disorders - Drugs In Development, 2023’, provides an overview of the Dermatological Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatological Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Drugs In Development, 2023’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Traumatic Brain Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Traumatic Brain Injury - Drugs In Development, 2023’, provides an overview of the Traumatic Brain Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Traumatic Brain Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MBF-362 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MBF-362 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MBF-362 in Solid Tumor Drug Details: MBF-362 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-8633 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-8633 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-8633 in Colorectal Cancer Drug Details: MT-8633 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LMN-101 in Traveler’s Diarrhea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LMN-101 in Traveler's Diarrhea report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LMN-101 in Traveler's Diarrhea Drug Details:LMN-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Botulinum Toxin Type A in Spasmodic Torticollis (Cervical Dystonia)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Botulinum Toxin Type A in Spasmodic Torticollis (Cervical Dystonia) Drug Details: Botulinum toxin A...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – it-hMSC in Dermatological Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - it-hMSC in Dermatological Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.It-hMSC in Dermatological Disorders Drug Details:Stem cell therapy (Stemedyne-MSC) is under development for...